Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

References

• PincusTCallahanLFWhat is the natural history of rheumatoid arthritis?Rheum Clin North Am199319123151
   PubMed Web of Science ®Google Scholar
• GibofskyAEpidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsisAm J Manag Care201420s128s14525180621
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis20147349250924161836
   PubMed Web of Science ®Google Scholar
• TanakaYNext stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?Ann Rheum Dis201372Suppl 2ii124ii12723253919
   PubMed Web of Science ®Google Scholar
• ShiGLiuYEditorial: biologics in autoimmune diseasesCurr Pharm Biotechnol20141550925213358
   PubMed Web of Science ®Google Scholar
• Enbrel (etanercept) [prescribing information]London, UKEuropean Medicines Agency last update May 30, 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000262/human_med_000764.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Humira (Adalimumab) [prescribing information]London, UKEuropean Medicines Agency last update October 21, 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp&mid=WC0b01ac058001d124Accessed May 30, 2014
   Google Scholar
• Remicade (infliximab) [prescribing information]London, UKEuropean Medicines Agency last update May 30, 2012. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000240/human_med_001023.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Orencia (Abatacept) [prescribing information]London, UKEuropean Medicines Agency last update October 21, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000701/WC500048935.pdf
   Google Scholar
• RoActemra (Tocilizumab) [prescribing information]London, UKEuropean Medicines Agency last update October 21, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf
   Google Scholar
• Cimzia (Certolizumab pegol) [prescribing information]London, UKEuropean Medicines Agency last update October 21, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf
   Google Scholar
• Kineret (Anakinra) [prescribing information]London, UKEuropean Medicines Agency last update October 21, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000363/WC500042310.pdf
   Google Scholar
• Simponi (Golimumab) [prescribing information]London, UKEuropean Medicines Agency last update October 21, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf
   Google Scholar
• Mabthera (Rituximab) [prescribing information]London, UKEuropean Medicines Agency last update October 21, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf
   Google Scholar
• SinghJAChristensenRWellsGAA network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overviewCMAJ200918178779619884297
   PubMed Web of Science ®Google Scholar
• Gaujoux-VialaCGossecLCantagrelARecommendations of the French Society for Rheumatology for managing rheumatoid arthritisJoint Bone Spine20148128729724986683
   PubMed Web of Science ®Google Scholar
• CannonGWDuVallSLHaroldsenCLPersistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritisJ Rheumatol2014411935194325128516
   PubMed Web of Science ®Google Scholar
• BendtzenKPersonalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonistsDiscov Med20131520121123636137
   PubMed Web of Science ®Google Scholar
• PunziLMatucci CerinicMCantiniFTreatment patterns of anti-TNF agents in Italy: an observational studyReumatismo201163182821509346
   PubMedGoogle Scholar
• MootsRJHaraouiBMatucci-CerinicMDifferences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practiceClin Exp Rheumatol201129263421345289
   PubMed Web of Science ®Google Scholar
• SchabertVFWatsonCJosephGJIversenPBurudpakdeeCHarrisonDJCosts of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care populationJ Manag Care Pharm20131962163024074008
   PubMed Web of Science ®Google Scholar
• SchabertVFWatsonCGandraSRGoodmanSFoxKMHarrisonDJAnnual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United StatesJ Med Econ20121526427522115327
   PubMedGoogle Scholar
• TangBRahmanMWatersHCCallegariPTreatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritisClin Ther2008301375138418691998
   PubMed Web of Science ®Google Scholar
• WuEChenLBirnbaumHYangECifaldiMCost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims dataCurr Med Res Opin2007231749175917588306
   PubMed Web of Science ®Google Scholar
• FautrelBVerstappenSMBoonenAEconomic consequences and potential benefitsBest Pract Res Clin Rheumatol20112560762422137927
   PubMed Web of Science ®Google Scholar
• Di BariMBalziDRobertsATPrognostic stratification of older persons based on simple administrative data: development and validation of the ‘Silver Code,’ to be used in emergency department triageJ Gerontol Biol Sci Med Sci201065159164
   Web of Science ®Google Scholar
• Ministry of Labour, Health and Social PoliciesAnnual reportMinistry of Labour, Health and Social Policies. Annual report on the hospitalization activity2005 Available from: http://www.ministerosalute.it/programmazione/sdo/sezDocumenti.jsp?id=148&label=osp
   Google Scholar
• GonnellaJSLouisDZGozumMVECallahanCABarnesCADisease Staging Clinical and Coded Criteria. Version 5.26Ann Arbor, MIThomson Medstat2010Accessed June 28, 2014
   Google Scholar
• BonafedeMMGandraSRWatsonCPrincicNFoxKMCost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysisAdv Ther20122923424822411424
   PubMed Web of Science ®Google Scholar
• DarkowTChastekBRosenblattLDose escalation among rheumatoid arthritis patients treated with infliximab or abatacept: comparison in claims data. [abstract]Arthritis Rheum201163Suppl 10122121305507
   PubMed Web of Science ®Google Scholar
• MiglioreABallantiELaganaBMartinLSFredianiBBiologic agents for rheumatoid arthritis: can we hypothesize new strategies of treatment?Med Hypotheses20148211712124321737
   PubMed Web of Science ®Google Scholar
• CaporaliRContiFAliverniniSRecommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. EfficacyClin Exp Rheumatol201129S7S1421906423
   PubMed Web of Science ®Google Scholar
• TayarJHSuarez-AlmazorMENew understanding and approaches to treatment in rheumatoid arthritisBr Med Bull20109420121420200013
   PubMed Web of Science ®Google Scholar
• JonssonBKobeltGSmolenJThe burden of rheumatoid arthritis and access to treatment: uptake of new therapiesEur J Health Econ20088Suppl 2S61S8618097697
   PubMed Web of Science ®Google Scholar
• Al-BishriJAttarSBassuniNComorbidity profile among patients with rheumatoid arthritis and the impact on prescriptions trendClin Med Insights Arthritis Musculoskelet Disord20136111823645988
   PubMedGoogle Scholar
• GaffoASaagKGCurtisJRTreatment of rheumatoid arthritisAm J Health Syst Pharm2006632451246517158693
   PubMed Web of Science ®Google Scholar
• OgaleSHitrayaEHenkHJPatterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskelet Disord20111220421929807
   PubMed Web of Science ®Google Scholar
• FidderHHSingendonkMMvan der HaveMOldenburgBvan OijenMGLow rates of adherence for tumor necrosis factor-alpha inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic reviewWorld J Gastroenterol2013194344435023885145
   PubMed Web of Science ®Google Scholar
• Degli EspostiLSangiorgiDPerroneVAdherence and resource use among patients treated with biologic drugs: findings from BEETLE studyClinicoecon Outcomes Res2014640140725258545
   PubMedGoogle Scholar
• FisherMDWatsonCFoxKMChenYWGandraSRDosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care populationCurr Med Res Opin20132956156823489410
   PubMed Web of Science ®Google Scholar
• MarchesoniAZaccaraEGorlaRTNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practiceAnn N Y Acad Sci2009117383784619758236
   PubMed Web of Science ®Google Scholar
• Ramirez-HerraizEEscudero-VilaplanaVAlañón-PlazaEEfficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practiceClin Exp Rheumatol20133155956523710583
   PubMed Web of Science ®Google Scholar
• HetlandMLChristensenIJTarpUDirect comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registryArthritis Rheum201062223220039405
   PubMed Web of Science ®Google Scholar
• SchabertVFBruceBFerrufinoCFDisability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness studyCurr Med Res Opin20122856958022236091
   PubMed Web of Science ®Google Scholar
• BonafedeMMGandraSRFoxKMWilsonKLTumor necrosis factor blocker dose escalation among biologic naive rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiationJ Med Econ20121563564322332705
   PubMedGoogle Scholar
• HarrisonDJHuangXGlobeDDosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritisAm J Health Syst Pharm2010671281128720651319
   PubMed Web of Science ®Google Scholar
• HuangXGuNYFoxKMHarrisonDJGlobeDComparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practiceCurr Med Res Opin2010261637164520429830
   PubMed Web of Science ®Google Scholar
• OllendorfDAKlingmanDHazardERaySDifferences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care populationClin Ther20093182583519446156
   PubMed Web of Science ®Google Scholar
• BlumeSWFoxKMJosephGChuangCCThomasJGandraSRTumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management settingAdv Ther20133051752723740359
   PubMed Web of Science ®Google Scholar
• GreenbergJDReedGDecktorDA comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registryAnn Rheum Dis2012711134114222294625
   PubMed Web of Science ®Google Scholar
• GilbertTDJrSmithDOllendorfDAPatterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskelet Disord2004513615485582
   PubMed Web of Science ®Google Scholar
• JoyceATGandraSRFoxKMSmithTWPillMWNational and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naive rheumatoid arthritis patients in US health plansJ Med Econ20141711024131136
   PubMedGoogle Scholar
• CurtisJRChenLLuijtensKDose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level dataArthritis Rheum2011632203220821484766
   PubMed Web of Science ®Google Scholar
• WeinblattMESchiffMHRudermanEMEfficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled studyArthritis Rheum2008581921193018576334
   PubMed Web of Science ®Google Scholar
• Drug usage analysis and health care resources consumption in patients with rheumatoid arthritisInternational Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European CongressAmsterdam (NL)2014 Value in Health177PMS6
   Google Scholar